245 Summer Street,
Boston , MA, 02210

Rank

Rank Universe
23 60

Summary

The fund seeks capital appreciation by investing in companies in the United States.

The investment process is designed to highlight companies that are engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes.

The process also focuses on companies that benefit significantly from scientific and technological advances in biotechnology.

Additiona More

Link

Directors

Oct 13, 2023
  • OSCAR MUNOZ
  • ROBERT A LAWRENCE
  • THOMAS A KENNEDY
  • BETTINA DOULTON
  • VICKI L FULLER
  • THOMAS P BOSTICK
  • PATRICIA L KAMPLING
  • DENNIS J DIRKS
  • DONALD F DONAHUE
  • MICHAEL E WILEY
  • SUSAN TOMASKY
  • DAVID M THOMAS
  • VIJAY ADVANI

Chief Compliance Officer

  • JASON POGORELEC

Fund Manager(s)

Price

  • $ 26.36 ( -0.14 )
    Nov 4, 2024
    Last Close
  • Net Assets
  • $1.7B
    Mar 27, 2024
  • Holding
  • 100
    Sep 25, 2024
    More

  • 52-Week High/Low
  • $26.91 - $17.02
  • Turnover
  • 43%
  • Expense Ratio
  • 1.73%

Documents

Prospectus

Annual Reports

Performance

YTD

-

3 Year

-9.6%

5 Year

16.69%

Best

62.44%

2013

Worst

-40.63%

2002

Alpha

FBTCX S&P 500

Chart +